All In Biotech

Drug Trial Radar · NCT07563881

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 333 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

333

Planned (sponsor's estimate)

Start

Jun 5, 2026

Primary completion

Jul 2029

Study completion Sep 2029

Sponsor

Lead sponsor
Rapport Therapeutics Inc.Industry
Sponsor type
Industry
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Conditions

  • Focal Seizure
  • Epilepsy
  • Focal Epilepsy

Interventions

  • RAP-219Drug

    RAP-219 high dose tablets administered orally daily

  • RAP-219Drug

    RAP-219 medium dose tablets administered orally daily

  • PlaceboOther

    Matching placebo tablets administered orally daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median Percent Change in Seizure FrequencyTime frame: End of double-blind treatment period (end of week 14) vs Baseline

Locations

24 sites in 4 countries. Site status is shown where the registry gives one.

  • Clinical Study Center

    Birmingham, Alabama · Recruiting

  • Clinical Study Center

    Palmdale, California · Recruiting

  • Clinical Study Center

    San Francisco, California · Recruiting

  • Clinical Study Center

    Gulf Breeze, Florida · Recruiting

  • Clinical Study Center

    Atlanta, Georgia · Recruiting

  • Clinical Study Center

    Boise, Idaho · Recruiting

  • Clinical Study Center

    Springfield, Illinois · Recruiting

  • Clinical Study Center

    Fort Wayne, Indiana · Recruiting

  • Clinical Study Center

    Bethesda, Maryland · Recruiting

  • Clinical Study Center

    Hackensack, New Jersey · Recruiting

  • Clinical Study Center

    Livingston, New Jersey · Recruiting

  • Clinical Study Center

    New York, New York · Recruiting

  • Clinical Study Center

    The Bronx, New York · Recruiting

  • Clinical Study Center

    Asheville, North Carolina · Recruiting

  • Clinical Study Center

    Cleveland, Ohio · Recruiting

  • Clinical Study Center

    Philadelphia, Pennsylvania · Recruiting

  • Clinical Study Center

    Richmond, Virginia · Recruiting

  • Clinical Study Center

    Melbourne, Australia · Recruiting

  • Clinical Study Center

    Sydney, Australia · Recruiting

  • Clinical Study Center

    Seoul, South Korea · Recruiting

  • Clinical Study Center

    Busan, Republic of Korea, South Korea · Recruiting

  • Clinical Study Center

    Seoul, Republic of Korea, South Korea · Recruiting

  • Clinical Study Center

    Seoul, Republic of Korea, South Korea · Recruiting

  • Clinical Study Center

    Plymouth, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.